Inhibikase Therapeutics (IKT) Assets (2020 - 2025)
Historic Assets for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $79.6 million.
- Inhibikase Therapeutics' Assets rose 171852.44% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 171852.44%. This contributed to the annual value of $98.6 million for FY2024, which is 57968.74% up from last year.
- Inhibikase Therapeutics' Assets amounted to $79.6 million in Q3 2025, which was up 171852.44% from $88.9 million recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Assets peaked at $98.6 million during Q4 2024, and registered a low of $4.4 million during Q3 2024.
- For the 5-year period, Inhibikase Therapeutics' Assets averaged around $39.1 million, with its median value being $28.6 million (2022).
- Per our database at Business Quant, Inhibikase Therapeutics' Assets crashed by 7552.18% in 2024 and then soared by 171852.44% in 2025.
- Inhibikase Therapeutics' Assets (Quarter) stood at $42.5 million in 2021, then crashed by 41.28% to $24.9 million in 2022, then tumbled by 41.83% to $14.5 million in 2023, then surged by 579.69% to $98.6 million in 2024, then fell by 19.28% to $79.6 million in 2025.
- Its Assets was $79.6 million in Q3 2025, compared to $88.9 million in Q2 2025 and $94.3 million in Q1 2025.